Search

ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences Conference

Press release

LEIDEN, Netherlands & CAMBRIDGE, Mass., May 02, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV.

May 02, 2025
ProQR Therapeutics Announces Results for the Fourth Quarter and Full Year 2014

Press release

LEIDEN, Netherlands, Feb. 26, 2015 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

February 26, 2015
ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023

Press release

LEIDEN, Netherlands & CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) --

May 09, 2023
ProQR Appoints John Maraganore, PhD, as Strategic Advisor to the Supervisory Board

Press release

LEIDEN, Netherlands & CAMBRIDGE, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

March 07, 2022
ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference

Press release

LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV.

September 28, 2023
ProQR In-licenses Worldwide Rights to Ophthalmology Drug Candidate from Ionis Pharmaceuticals

Press release

ProQR receives exclusive worldwide license for IONIS-RHO-2.5Rx, now QR-1123, for autosomal dominant retinitis pigmentosa (adRP), a rare inherited form of blindness with no approved therapy

October 29, 2018
ProQR to Present Axiomer RNA Editing Platform Technology at RNA Editing Summit

Press release

LEIDEN, Netherlands & CAMBRIDGE, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

April 04, 2022
ProQR lizenziert weltweite Rechte für Arzneimittelkandidaten für die Augenheilkunde von Ionis Pharmaceuticals

Press release

ProQR erhält die exklusive weltweite Lizenz für IONIS-RHO-2.5Rx, jetzt QR-1123, für autosomal-dominante Retinitis pigmentosa (adRP), eine seltene vererbte Form der Blindheit ohne zugelassene Therapie

October 30, 2018
ProQR to Present at 3rd Annual Evercore ISI Virtual HealthCONx Conference

Press release

LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 18, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

November 18, 2020
ProQR Announces Successful Defense of a Key Axiomer® Patent Protecting ADAR-mediated RNA Editing

Press release

… ProQR Announces Successful Defense of a Key Axiomer® Patent … (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through … Patent Office (EPO) by two separate strawmen against ProQR’s granted patent EP 3234134 B1 , which is related to …

March 14, 2023